PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2012; 7(4): e35582.
Published online Apr 25, 2012. doi:  10.1371/journal.pone.0035582
PMCID: PMC3338416
A Chemocentric Approach to the Identification of Cancer Targets
Beáta Flachner,1 Zsolt Lörincz,1 Angelo Carotti,2 Orazio Nicolotti,2 Praveena Kuchipudi,3 Nikita Remez,3 Ferran Sanz,3 József Tóvári,4 Miklós J. Szabó,5 Béla Bertók,5 Sándor Cseh,1 Jordi Mestres,3* and György Dormán1*
1TargetEx, Dunakeszi, Hungary
2Medicinal Chemistry Department, University of Bari “Aldo Moro”, Bari, Italy
3IMIM – Hospital del Mar Research Institute and Universitat Pompeu Fabra, Barcelona, Catalonia, Spain
4National Institute of Oncology, Budapest, Hungary
5AMRI Hungary Zrt., Budapest, Hungary
Steve Horvath, Editor
University of California Los Angeles, United States of America
* E-mail: jmestres/at/imim.es (JM); dorman/at/target-ex.com (GD)
Conceived and designed the experiments: AC FS BB SC JM GD. Performed the experiments: BF ZL JT SC. Analyzed the data: JM GD. Wrote the paper: JM GD. Performed the calculations: ON PK NR MJS. All authors read and approved the final manuscript.
Received July 15, 2011; Accepted March 19, 2012.
A novel chemocentric approach to identifying cancer-relevant targets is introduced. Starting with a large chemical collection, the strategy uses the list of small molecule hits arising from a differential cytotoxicity screening on tumor HCT116 and normal MRC-5 cell lines to identify proteins associated with cancer emerging from a differential virtual target profiling of the most selective compounds detected in both cell lines. It is shown that this smart combination of differential in vitro and in silico screenings (DIVISS) is capable of detecting a list of proteins that are already well accepted cancer drug targets, while complementing it with additional proteins that, targeted selectively or in combination with others, could lead to synergistic benefits for cancer therapeutics. The complete list of 115 proteins identified as being hit uniquely by compounds showing selective antiproliferative effects for tumor cell lines is provided.
Cancer is a disease of the cell [1]. This rather simple statement implies an enormous complexity when attempting to identify efficacious anticancer agents. One of the major issues associated with anticancer research is that traditional target-directed strategies are confronted with the essentiality of the function of the target in healthy cells. Inevitably, targeting proteins that have essential functions are likely to lead to chemical entities with narrow therapeutic windows and significant toxic effects [2]. An additional challenge is the unstable epigenetic and genetic status of cancer cells, undergoing multiple mutations, gene copy alterations, and chromosomal abnormalities that have a direct impact on the efficacy of anticancer agents at different stages of the disease [3]. All these aspects make cancer drug discovery extremely difficult and have led to poor clinical approval success rates compared to other therapeutic areas [2].
The advent of high-throughput cell-based cytotoxicity assays opened new perspectives for anticancer discovery [4]. The implementation of differential cytotoxicity screens marked the departure from small molecule screens on preconceived individual protein targets and allowed the identification of small molecules potentially acting through a richness of mechanisms of action [5], while showing at the same time selective antiproliferative effects in cancer cells compared to healthy cells [6]. However, as recently pointed out [1], for those cell-based strategies to have a true impact in cancer drug discovery, means to uncover the target profile of bioactive small molecules in antiproliferative or toxicity assays are absolutely necessary. In this respect, extensive proteomic profiling is often applied subsequently to identify differentially expressed proteins in cancer cell lines that may explain the biological effect of small molecule hits [7], [8]. However, profiling the cellular activities of molecular libraries is both technically and logistically a laborious task [9] and thus, alternative approaches for fast and efficient profiling of hundreds of compounds on thousands of proteins are required.
In recent years, the availability of an increasing amount of protein-ligand interaction data in the public domain has promoted the development of ligand-based computational methods aiming at predicting the affinity profile of small molecules across multiple targets [10]. An early application of these initiatives was the prediction of the biological activity spectrum of all small molecules contained in the National Cancer Institute database [11]. Lately, virtual target profiling was successfully used to identify new targets for known drugs [12], to predict the mechanism of action of antimalarials discovered in a high-throughput cell-based screen [13], and to suggest the targets against which selected compounds from a chemical library should be tested, leading to the identification of novel antagonists for all four members of the adenosine receptor family [14]. Given the current levels of performance achieved, in terms of sensitivity and specificity, against experimentally-determined complete ligand-protein interaction matrices [15], these methods are emerging as a true fast and efficient alternative to the more laborious proteomic profiling.
The integration of differential cytotoxicity screening and virtual target profiling for the identification of cancer-relevant targets was put into practice within the context of CancerGrid, a European Commission project under Framework Programme 6 [16]. Details on the approach followed and the results achieved are discussed in the following sections.
For the sake of clarity, a summary scheme of the overall differential in vitro and in silico screening (DIVISS) process followed in this work is depicted in Figure 1. Starting with a chemical collection of 30,000 compounds, differential cytotoxicity screening resulted in the identification of two sets of small molecule hits showing selective antiproliferative effects for tumor and healthy cells, respectively, which by virtual target profiling led ultimately to the identification of a list of 115 proteins of potential relevance to cancer. Details of the results obtained at each stage of this novel chemocentric approach to cancer target identification are provided next.
Figure 1
Figure 1
Schematic flowchart of the DIVISS approach applied in this work leading to the identification of 115 proteins of potential relevance to cancer.
High-throughput cytotoxicity screening
A cell-based cytotoxicity screening campaign was performed on a chemical collection composed of 30,000 diverse molecules selected mainly from the entire AMRI catalogue [17]. Single point screening of these compounds at 50 µM concentration was completed in duplicate on a colon cancer HCT116 cell line. The correlation of the two independent viability values determined for each compound is depicted in Figure 2a. An average Z′ factor of 0.58 was derived from analysis of these duplicate data, which is indicative of the quality of the assay and the data obtained. The distribution of the number of compounds resulting in different average percentages of cell viability is provided in Figure 2b. As can be observed, almost 50% of the compounds had basically no effect on the viability of the HCT116 cells. But most interestingly, over 13% of the compounds showed remarkable toxic effects on HCT116 cells, with viability values of 20% or lower. This cytotoxic set of 4,158 compounds was selected for a follow-up dose-response screening.
Figure 2
Figure 2
a) Correlation of two independent viability values determined for the same compound and b) distribution of viability values for the chemical library of 30,000 compounds.
Differential cytotoxicity dose-response screening
To optimise our capacity of dose-response screening, a diverse set of 2,000 molecules was first selected from the 4,158 cytotoxic compounds identified in the previous high-throughput screening campaign [18]. Dose-response curves on both tumor HCT116 and normal MRC-5 cells were determined in duplicate for these 2,000 compounds. To identify those small molecules that have levels of toxicity on tumor cells significantly higher than those observed on healthy cells, the ratio between the IC50 values obtained in MRC-5 cells, IC50 (MRC-5), and those obtained in HCT116 cells, IC50 (HCT116), was derived for each compound. A total of 230 compounds were identified to be 5 times or more cytotoxic in tumor cells than in healthy cells (IC50 MRC-5/IC50 HCT116≥5). A chemotype clustering analysis [19] was then performed on this first set of 2,000 compounds for which dose-response data was produced. A cytotoxicity enrichment score was then assigned to each chemotype cluster based on its relative presence in the set of 230 compounds showing most selective antiproliferative effects on tumor cells. Those chemotypes having higher than 20% hit rate were selected and used to recover compounds from the remaining 2,158 for which only single-point measurements were available. This bias towards selective tumor cytotoxic chemotypes led to the identification of 150 compounds that were complemented with an additional set of 330 compounds added on the basis of diversity criteria [18]. Dose-response curves on both cell lines were obtained in duplicate for these 480 compounds, from which an additional set of 35 compounds was identified as having cytotoxic selectivity for tumor cells relative to healthy cells. Altogether, 2,480 compounds went through differential cytotoxicity dose-response in vitro screening, leading to the identification of 265 compounds with selective cytotoxicity for tumor cells (Figure 1). Overall, 119,520 cytotoxicity data points were generated, 60,000 from the primary cytotoxicity screenings on HCT116 cells (30,000 compounds in duplicate) and 59,520 from the dose-response screenings (2,480 compounds at 6 concentrations in duplicate on two cell lines), which represents a significant screening effort.
The distributions of the resulting average IC50 values for all 2,480 compounds on tumor HCT116 and normal MRC-5 cells are illustrated in Figure 3a. The fact that most screened compounds have determined IC50 values below 25 µM is a good indication of the validity of the first screening. In this respect, just over 12% of the compounds for tumor cells, compared to the almost 26% for normal cells, gave an IC50 value above 25 µM, whereas 25% and 22% of the compounds screened on tumor and normal cells, respectively, returned an IC50 value below 5 µM. The final distribution of the cytotoxicity ratios per compound is provided in Figure 3b, where large values are associated to promising compounds having some degree of selective cytotoxicity for tumor cells relative to healthy cells. As can be observed, the vast majority of compounds (over 60%) returned cytotoxicity ratios between 0.5 and 2 meaning that they were basically unselective between tumor and healthy cells. But most interestingly, 711 compounds (29%) were found to be 2 times or more cytotoxic in tumor cells than in healthy cells, with 265 of them showing cytotoxicity ratios above 5. In contrast, 277 compounds (11%) were found to be 2 times or more cytotoxic in healthy cells than in tumor cells, with 251 of them having cytotoxicity ratios below 0.2. These two sets of 265 and 251 compounds (Figures S1 and S2) showing selective antiproliferative effects for tumor and normal cells, respectively, will be carried over to the next phase of virtual target profiling (Figure 1). A similarity analysis (Figure S3) highlighted the diversity of chemical structures within each set but also between the two sets, a point worth stressing in support of phenotypic screening approaches over target-directed strategies for complex diseases.
Figure 3
Figure 3
a) Distribution of the cytotoxicity (IC50 values) of the selected compounds on HCT116 and MRC5 cells and b) distribution of the selective cytotoxicity against HCT116. NT means “non toxic”.
Virtual target profiling
Each one of the two cell-line selective compound sets was processed in silico against the 4,643 ligand-based protein models derived from publicly available resources [20][28] using a validated similarity-based approach described earlier [14], [15]. With regards to the 265 selective tumor cytotoxic compounds, at least one target interaction was predicted for 173 of them (65%), reflecting that the chemical space defined by the set of tumor selective compounds was decently covered by small molecules present in public chemogenomic databases. For these compounds, a total of 2,356 molecule-protein interactions were predicted. Of those, 818 interactions between 139 molecules and 229 proteins were predicted to have activities of 1 µM or better (pAct≥6), meaning that on average each tumor selective compound was expected to potentially interact with 6 targets. In comparison, at least one target interaction was predicted for 117 of the 251 selective cytotoxic compounds on normal cells (47%), meaning that 53% of those compounds was found to be outside the applicability domain defined by small molecules in public chemogenomic databases [15]. For these compounds, a total of 1,023 molecule-protein interactions were predicted. Of those, 463 interactions between 84 molecules and 160 proteins were predicted to have activities of 1 µM or better (pAct≥6), resulting in an average number of 5 interacting proteins per compound.
A comparative analysis of the predicted interactions from the two cell-line selective compound sets allows gaining a better insight on the proteins likely to be differentially relevant for tumor cell lines. The results are illustrated in the Venn diagram depicted in Figure 4a, which schematically shows the degree of overlap and uniqueness between the two target lists. In this respect, it was found that up to 114 proteins were predicted to be hit at least once by some compound in either set, with the list of proteins being mainly composed by G protein-coupled receptors (45%) and enzymes (37%). In contrast, only 46 proteins were found to be solely hit by compounds with selective cytotoxicity for healthy cells, with a distribution among protein families very similar to the one obtained previously for the list of shared proteins (41% of G protein-coupled receptors and 37% of enzymes). But most interestingly, a list of 115 proteins hit uniquely by compounds with selective cytotoxicity for tumor cells was identified (Table S1). Analysis of its composition among the main protein families of therapeutic relevance reveals a clearly differentiated signature from the other two lists of proteins. As shown in Figure 4b, the list is mainly composed of enzymes (58%) and the presence of G protein-coupled receptors has been reduced significantly (16%). To complement this picture, Figure 4c provides the class distribution of the 67 enzymes found in this list. A clear bias towards transferases (43%) is observed, very much in agreement with the importance conferred to kinases as therapeutic targets for cancer [29], [30].
Figure 4
Figure 4
a) Venn diagram of the protein targets predicted for the selective cytotoxic compounds to HCT116 and MRC-5 cell lines; b) distribution across protein families of the 115 targets predicted to interact uniquely with selective cytotoxic compounds to tumor (more ...)
Proof of concept
It may not escape the scrutinous eye of the cancer researcher that within the list of 115 potential tumor selective proteins (Table S1) there are two widely recognized anticancer targets, namely, histone deacetylases (HDACs) and heat shock protein 90-alpha (HSP90), both of which known to be expressed in colon cancer HCT116 cell lines [7], [8] and to confer tumor selectivity upon small molecule inhibition [31], [32]. Accordingly, in an attempt to close the cycle of the DIVISS approach presented above, inhibitors of these two targets were used to exemplify at this stage that indeed selective antiproliferative effects can be achieved on the tumor HCT116 and normal MRC-5 cell lines used in this work.
To this end, suberoylanilide hydroxamic acid (SAHA) and 17-(allylamino)-17-demethoxygeldanamycin (17AAG) were selected as representative pan-HDAC and HSP90 inhibitors, respectively. Dose-response curves on both HCT116 and MRC-5 cell lines were determined for the two inhibitors (Figure S4). The results confirmed that both compounds inhibited the proliferation of HCT116 cells in a dose dependent manner, while having little or no effect on MRC-5 cells. In particular, the IC50 values of SAHA and 17AAG on HCT116 cells were 0.64 µM and 0.2 µM, respectively, which resulted in 781 and 93 fold selectivity, respectively, relative to the antiproliferative effect on MRC-5 cells. These observations provide confirmation of the ability of the DIVISS approach for identifying cancer-relevant targets.
We checked also whether within the set of 265 compounds showing selective antiproliferative effects for tumor cell lines there was any compound that could have been tested on a range of colon cancer cell lines and for which screening data was also available in the public domain. Much to our surprise, we found experimental data in PubChem [23] for eight compounds that were also present in our tumor selective set (Table S2). Among them, five compounds are reported to have affinity for the amine oxidase flavin-containing B enzyme (MAO-B), a target present in our list of 115 putative cancer-relavant proteins (Table S1). But, most interestingly, one of them, NSC680350 (CID 387030), was reported to have an IC50 of 80 nM for MAO-B, in good agreement with our predictions. In addition, it was also tested at multiple human tumor cell lines, including six colon cancer cell lines. Among them, the pGI50 value reported in PubChem for colon HCT116 cell lines (4.64) is, within the variability limits of this type of experiments, in good agreement with the pGI50 value obtained in this work for the same type of cell lines (5.19). The dose-response curve of the cytotoxicity of NSC680350 on HCT116 cell lines in this work and a summary of all colon cancer data found in PubChem for this compound is provided in Figure S5.
Substantiation of the potential relevance to cancer of the list of 115 proteins identified as being targeted solely by tumor selective compounds was performed by two independent perspectives. On the one hand, all 115 proteins were scored on the basis of recently derived oncogene probabilities (OncoScores) and checked for currently available experimental data on the up- and down-regulation in colon cancer samples [33], [34]. On the other hand, we used all drug-target interaction data available from public resources [20][28] to rank order all drugs based on the number of known targets within the list of 115 proteins and check for whether cancer was the primary indication among the top ranked. The results provide ample support for the use of the DIVISS approach to identifying cancer-relevant targets.
The OncoScores for all 115 proteins targeted by tumor selective compounds were obtained from the CGPrio website [34]. To assess whether this list of proteins is enriched with probable oncogenes with respect to other lists of proteins, OncoScores were also calculated for all the 46 proteins targeted by normal selective compounds and the 114 proteins shared by the two sets of cell-line selective compounds. The trends of the cumulative percentage of proteins with OncoScores above a certain probability value found within each list are displayed in Figure 5. As can be observed, it is found that 36.5% of the 115 proteins targeted by tumor selective compounds have an oncogene probability above 0.7 and that, under the same OncoScore cutoff, this percentage is significantly higher than the 8.7% and 19.3% of the 46 proteins targeted by normal selective compounds and the 114 proteins shared by the two sets of compounds, respectively. Having provided evidence that this selection of 115 tumor selective proteins is enriched with putative oncogenes, the IntOGen platform [33] was then used to inspect whether any protein from the list was in addition known to be significantly altered (corrected p-value <0.05) in terms of up- or down-regulation in colon cancer. A total of 29 of those proteins (25%) could indeed be confirmed to be significantly altered in colon cancer, 10 of which having an OncoScore above 0.7. The OncoScores and regulation marks for the whole list of 115 tumor selective proteins are provided Table S1.
Figure 5
Figure 5
Distribution of oncogene probabilities for the proteins predicted uniquely for compounds selective to HCT116 (black) and MRC-5 (light grey) and the proteins found in both selective sets (dark grey).
The subset of 42 tumor selective proteins with OncoScore higher than 0.7 is provided in Table 1. Not surprisingly, its composition is highly biased by protein kinases (52%), although there is also an important representation (21%) of transcription factors. Of mention is however the fact that a couple of G protein-coupled receptors (GPCRs) are found in this highly probable oncogene subset, namely, the D(1A) dopamine receptor (DRD1) and the sphingosine 1-phosphate receptor 1 (S1PR1). GPCRs have traditionally been regarded as the main targets for diseases of the central nervous system. But most interestingly, the relevance of GPCRs in cancer drug discovery was revisited recently and the potential role of S1PR1 in particular highlighted [35].
Table 1
Table 1
List of 42 proteins with OncoScore >0.7 among the 115 proteins identified by the DIVISS approach.
A close look at the top-20 ranked proteins present in Table 1 reveals that the list contains proteins that may be somewhat unexpected from the viewpoint of its relationship to colorectal cancer. For example, the androgen (AR) and estrogen (both ESR1 and ESR2) nuclear hormone receptors are known to be relevant in prostate and breast cancers, and the alpha-type platelet-derived (PDGFRA) and epidermal (EGFR) growth factor receptors are recognised angiogenesis factors. However, recent studies suggest a role in intestinal carcinogenesis for nuclear receptors in general [36] and growth factor receptors [37], including precisely AR [38], ESR1 [39], ESR2 [40], PDGFRA [41] and EGFR [42]. PDGFRA in particular is also known to be significantly down-regulated in colon cancer [33]. In addition, further evidences exist in the literature of drugs targeting primarily some of those targets and having an effect on the proliferation of human colorectal tumour cell lines, including HCT116 [40], [43]. Among them, raloxifene is a high affinity binder of both ESR1 and ESR2 and has been reported to inhibit HCT116 cell growth in a dose-dependent manner [40] and afatinib is a potent EGFR inhibitor that was recently shown to inhibit the growth of HCT116 cell lines with an IC50 value of 1.62 µM [43]. These examples provide ample bibliographical support to the relevance in colon cancer for some of those proteins that would have been otherwise completely overlooked.
It may also surprise that currently recognised cancer targets, such as HSP90, are not present in Table 1. In this particular case, the target is indeed contained in the full list of 115 proteins provided in Table S1 but with a low OncoScore = 0.023. It is thus worth stressing here that CGPrio [34] is a machine learning method based on the differential properties of known cancer genes and on the assumption that genes with similar properties (including sequence conservation, protein domains and interactions, and regulatory data) to known cancer genes are more likely to be involved in cancer. It is used here as a prioritization method, as it has been shown that a large percentage of new cancer genes have high CGPrio probabilities [33], [34], but it doesn't mean that absolutely all cancer genes share these properties, and thus there may well be some bona fide cancer targets, such as HSP90, with a low CGPrio probability. In this respect, the low OncoScore obtained for HSP90 means only that, on the basis of current knowledge on cancer genes, HSP90 does not share properties with the rest of cancer genes for which information is available. Taken together, these results emphasize the potential applicability of the DIVISS approach as a complementary strategy to the identification of cancer-relevant targets.
The BioCarta resource [44] was then used to perform an analysis of the main pathways in which these 42 highly probable oncogenes are involved. A total of 131 pathways were retrieved, with 68 of them (52%) having two or more proteins and only 9 (7%) containing five or more proteins. The latter group is composed mainly of signaling pathways. Among them, the MAPKinase signaling pathway contains seven of those probable oncogenes, namely, BRAF, MAP2K1, MAP3K8, MAPK10, RAF1, STAT1, and TGFBR1, and the Erk1/Erk2 MAPK signaling pathway involves six of them, namely, EGFR, MAP2K1, PDGFRA, RAF1, SRC, and STAT3 (see Table 1). The remaining 7 pathways are the Bioactive peptide induced, EGF, and PDGF signaling pathways, the signaling of hepatocyte growth factor receptor, and the ones defining the role of ERBB2 in signal transduction and oncology, the CARM1 and regulation of the estrogen receptor, and the sumoylation by RANBP2 regulates transcriptional repression, all involving 5 of those probable oncogenes (Table 1). The link between some of these pathways and cancer has been already recognised in previous studies [45], [46].
In recent years, the amount of publicly available in vitro data on the interaction of drugs with multiple proteins has increased dramatically [20][28]. Analysis of these data has revealed that most cancer drugs are multitarget agents rather than selective molecules [47]. Accordingly, we took the list of 115 targets hit by selective compounds on HCT116 and performed a search for those drugs that, based on currently available affinity data determined experimentally [20][28], would show at least micromolar affinity on the largest number of those targets. Figure 6 collects the results obtained for the 20 drugs having at least micromolar affinity for more than 5 tumor selective proteins. Remarkably, 18 of those drugs have cancer as their primary indication, 4 of which target mainly HDACs, whereas the other 14 have different affinity profiles on a wide range of kinases. The presence of chlorpromazine and amitriptyline in this list, indicated for psychosis and depression, respectively, and targeting mainly GPCRs instead of HDACs or kinases, may come as a surprise at this stage. However, in the line of what was previously mentioned about the new perception of GPCRs in cancer [35], recent reports indicate that chlorpromazine, potentially through its action on multiple tumor selective GPCRs, can change influx properties of membranes and that this property makes it a promising chemosensitizing compound for enhancing the cytotoxic effect of tamoxifen, an antagonist of the estrogen receptor, present also in the list of 115 tumor selective proteins [48]. From a drug perspective, these results provide further support to the relevance for cancer of the 115 proteins identified.
Figure 6
Figure 6
Profiles of experimental affinity data of the 20 drugs, among 4,819, hitting more than 5 targets found solely in tumor selective compounds.
There are two recognisable extensions to the version of the DIVISS approach presented here. The first obvious extension is in the use of other cell lines. In this particular study, HCT116 and MRC-5 cell lines have been taken as models of tumor and healthy cell lines, respectively. However, there are numerous alternative human tumor cell lines that can be used instead and those can in turn be differentially compared to several healthy cell lines as well [49]. Accordingly, differential anticancer screens on each particular combination of tumor and healthy cell lines will in principle lead to different, yet complementary, lists of cancer-relevant targets. The second potential extension is in the coverage of larger chemical spaces, an aspect that is inherent to any screening campaign. The present study focussed on a diverse selection of 30,000 molecules from the AMRI catalogue, currently containing over 240,000 compounds. The size and nature of the chemical library used in the differential cytotoxicity screens essentially determines the number and diversity of small molecule hits identified and they ultimately define the type of targets that, by means of in silico target profiling, will be selectively associated to each cell line.
Conclusions
Cell systems are implicitly robust and selectively acting on one particular target may not be the most efficacious way of modulating or interfering with them as the system may always find ways to compensate for the selective perturbation incorporated. Instead, targeting multiple essential targets in tumor cells may be a more efficient strategy to make more difficult for the cell system to compensate for all perturbations introduced. Indeed, recent evidences indicate that most cancer drugs attain their in vivo efficacy through modulation of multiple targets rather than selective interaction on a single target. The big question is then defining the essential protein signature of each cancer type, so it can be thoroughly addressed by novel cancer therapeutic agents [50]. The DIVISS strategy presented here represents a novel chemocentric approach to the identification of cancer-relevant drug targets that complements efficiently other established bioinformatics and functional approaches [51], [52] and thus may contribute to increasing our confidence on potential drug targets [53].
Screening Library
The CancerGrid consortium had privileged access to the entire chemical catalogue at AMRI [17], currently containing 241,000 compounds and found particularly relevant for drug discovery purposes in a comparative analysis of 23 supplier databases [54]. This relatively vast, diverse and unique chemical space was complemented with a focused set of 1,500 compounds synthesized at the University of Bari. To adjust the number of compounds to our screening capacity, an optimal diversity selection was performed [55]. The final screening collection was limited to a diverse selection of 30,000 compounds, a number that was fitting optimally our capacity for cytotoxicity screening.
Cell types and culture conditions
A colon adenocarcinoma (HCT116) and normal human lung fibroblast (MRC-5) cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA). HCT116 cells were maintained in McCoy's 5a Modified Medium supplemented with 10% FBS, 100 units/ml penicillin, and 100 µg/ml streptomycin at 37°C in a humidified 5% CO2 incubator. Subculturing was done using 1[ratio]5 ratio twice a week. MRC-5 cells were maintained in DMEM supplemented with 10% FBS, 100 units/ml penicillin, and 100 µg/ml streptomycin at 37°C in a humidified 5% CO2 incubator. Subculturing was done using 1[ratio]3 ratio twice a week. A cell bank was established for the cell lines used during the differential toxicity screening campaign. In all experiments, the doubling time between cancer and normal cells was approximately 24 hours.
Assay developments and validation
The high-throughput in vitro assay for measuring toxicity and antiproliferative effects of small molecules was implemented as described earlier [56]. Cell lines were grown in culture flasks to 90% confluences, then harvested in counted cell density and seeded into 384-well microtiter plates. Test compounds were then added in various concentrations (in 2% DMSO final concentration) and incubated with the cells in CO2 incubators at 37°C for 48 h. This incubation period has the advantage of allowing those compounds that are not directly toxic but can block or slow down cell proliferation to have enough time to show their effect. During this period, FBS content of the medium was decreased to avoid the masking effect of FBS on toxicity. Detection of viability is based on the reduction of resazurin (Alamar blue) by living cells, resulting in an increased fluorescent signal [57]. For the transformation of the assay into a high-throughput format, a Beckman Biomek liquid handling system and a Wallac Victor plate reader were used. Protocols needed for handling the 384-well plates were established for both single-concentration screening and dose-response curve determination. A plate map was used for the validation of the assay on 384-well plates, which is suitable for the determination of dose-response curves for 16 compounds at the same time using 6 concentrations in triplicate. This experiment was run in parallel on 5 plates and repeated three times on different days. From the dose-response curves, IC50 values were determined and analyzed. To test the reproducibility and robustness of the assay for high-throughput screening, Z′ factors (~0.72) and S/B ratios (~10) were determined and the respective plate-to-plate and day-to-day coefficients of variation found to be 5.0%, 2.7%, 1.7% and 5.6%. Based on the established assay protocol, single-point screenings were done at 50 µM compound concentration in duplicate. Likewise, IC50 values were obtained from the toxicity dose-response curves from six compound concentrations in duplicate and calculated with Microcal Origin 5.0. Compounds showing selective cytotoxicity for tumor cells relative to healthy cells are identified by large values of the ratio IC50(MRC-5)/IC50(HCT116), whereas the inverse of this ratio serves to recognize compounds with selective cytotoxicity for healthy cells relative to tumor cells.
Chemogenomic databases
There are currently several public sources that contain chemical structures with information on the binding or functional activity to protein targets. Those used in the present work include ChEMBLdb [20], PDSP [21], IUPHARdb [22], PubChem [23], DrugBank [24], BindingDB [25], BindingMOAD [26], AffinDB [27], and NRacl [28]. Altogether contain a total of 329,303 unique ligands with 1,505,348 interactions to 4,643 unique proteins. Among them, there are 4,819 small-molecule drugs with 30,875 interactions to 4,120 unique protein targets.
Affinity predictions and validation
To be processed efficiently, molecular structure information needs to be encoded using some sort of mathematical descriptors. In this work, three types of two-dimensional descriptors were used, namely, SHED, FPD, and PHRAG [58], [59], each one of them characterizing chemical structures with a different degree of fuzziness and thus complementing each other in terms of structural similarity and hopping abilities. For any biological target under study, the ensemble of molecular descriptors capturing the structural and pharmacophoric features of all molecules for which affinity data is publicly available from chemogenomic databases represents a mathematical description of this target from a chemical perspective. On this basis, the affinity of a compound for a given target can be estimated by inverse distance weighting interpolation of the experimental affinities from all neighboring molecules found within a pre-determined applicability domain [15]. Based on the ligand-based target models defined from all the pharmacological data available in chemogenomic databases, each small molecule can be currently processed against 4,643 proteins. The output returns a list of the targets for which affinity is predicted for every query molecule. The method has been successfully validated retrospectively, on its ability to predict the entire experimental interaction matrix between 13 antipsychotic drugs and 34 protein targets [15], but also prospectively, on its capacity to identify the correct targets for all molecules contained in a biologically-orphan chemical library [14] and to correctly anticipate the affinity profile of the drug cyclobenzaprine on a panel of 8 protein targets [60].
Oncogene expression and probabilities
Expression profiles for proteins in various types of cancer were directly extracted from IntOGen [33]. IntOGen is a framework that currently contains and integrates data from almost 800 independent experiments collecting transcriptomic alterations, genomic gains and losses, and somatic mutation information in different human cancer types. Oncogene probabilities (OncoScores) were calculated with CGPrio [34] using the PC-GS-PD-PI-RD dataset that integrates a set of heterogeneous data accounting for protein conservation (PC), gene structure (GS), protein domains (PD), protein-protein interactions (PI), and regulatory data (RD).
Small molecule inhibitors
SAHA, a pan-HDAC inhibitor, was kindly provided by Ciro Mercurio (DAC s.r.l., Milan, Italy) with 95% purity and 17AAG, a HSP90 inhibitor, was obtained from Sigma (St Louis, MO) with 95% purity.
Figure S1
Distributions of pairwise similarities using PHRAGS (top) and PFPD (bottom) descriptors between compounds with selective cytotoxicity in HCT116 cell lines (left), MRC-5 cell lines (middle), and HCT116 and MRC-5 cell lines (right).
(PDF)
Figure S2
List of chemical structures showing selective cytotoxicity for HCT116 cell lines.
(PDF)
Figure S3
List of chemical structures showing selective cytotoxicity for MRC-5 cell lines.
(PDF)
Figure S4
Dose-response curves of 17AAG, an HSP90 inhibitor (left), and SAHA, a HDAC inhibitor (right), on the HCT116 and MRC-5 cell lines.
(PDF)
Figure S5
Dose-response curve (left) of the cytotoxicity of compound NSC680350 (CID 387030; internally known as MC-309) on HCT116 cell lines (GI50 = 6.4 µM). Also provided (right) are the pGI50 values of the compound on the two cell lines tested in this work and the six colon cancer cell lines for which data is available in PubChem.
(PDF)
Table S1
List of all 115 proteins identified by the DIVISS approach as from small molecule hits selective to HCT116 relative to MRC-5. The OncoScore is the oncogene probability calculated with CGPrio [34]. The arrows next to the gene name mark the set of 29 proteins that are known to be significantly altered (corrected p-value <0.05) in terms of up- or down-regulation in colon cancer, as extracted from the IntOGen platform [33].
(DOC)
Table S2
List of all interactions available in PubChem for compounds present within the list of 265 cytotoxic selective in HCT116 cell lines.
(DOC)
Acknowledgments
We acknowledge the contributions from all partners to the CancerGrid Project, namely, AMRI Hungary Zrt., DAC s.r.l., Inte:ligand GmbH, GKI Economic Research Co., MTA SZTAKI, Tallinn University of Technology, TargetEx llc, University of Bari “Aldo Moro”, University of Helsinki, University of Jerusalem, and Universitat Pompeu Fabra.
Footnotes
Competing Interests: The authors have read the journal's policy and have the following conflicts: Beáta Flachner, Zsolt Lörincz, Sándor Cseh, and György Dormán are full-time paid employees of TargetEx, Dunakeszi, Hungary, and Miklós J. Szabó and Béla Bertók are full-time employees of AMRI Hungary Zrt., Budapest, Hungary. Jordi Mestres is President of Chemotargets SL. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Funding: This work was supported by a grant from the European Comission (CancerGrid, FP-6 LCHC-CT-2006-037559), http://ec.europa.eu/research/fp6/index_en.cfm. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
1. Caldwell JS. Cancer cell-based genomic and small molecule screens. Adv Cancer Res. 2007;96:145–173. [PubMed]
2. Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nat Rev Drug Discov. 2007;6:115–120. [PubMed]
3. Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, et al. Genetic and epigenetic heterogeneity in cancer: the ultimate challenge for drug therapy. Curr Drug Targets. 2010;11:1304–1316. [PubMed]
4. Slater K. Cytotoxicity tests for high-throughput drug discovery. Curr Opin Biotechnol. 2001;12:70–74. [PubMed]
5. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Jr, et al. An information-intensive approach to the molecular pharmacology of cancer. Science. 1997;275:343–349. [PubMed]
6. de Bono JS, Tolcher AW, Rowinsky EK. The future of cytotoxic therapy: selective cytotoxicity based on biology is the key. Breast Cancer Res. 2003;5:154–159. [PMC free article] [PubMed]
7. Lou J, Fatima N, Xiao Z, Stauffer S, Smythers G, et al. Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells. Cancer Epidemiol Biomarkers Prev. 2006;15:1598–1606. [PubMed]
8. Beck HC, Petersen J, Nielsen SJ, Morszeck C, Jensen PB, et al. Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat. Electrophoresis. 2010;31:2714–2721. [PubMed]
9. Melnick JS, Janes J, Kim S, Chang JY, Sipes DG, et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci USA. 2006;103:3153–3158. [PubMed]
10. Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol. 2007;152:9–20. [PubMed]
11. Poroikov VV, Filimonov DA, Ihlenfeldt WD, Gloriozova TA, Lagunin AA, et al. PASS biological activity spectrum predictions in the enhanced open NCI database browser. J Chem Inf Comput Sci. 2003;43:228–236. [PubMed]
12. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. Predicting new molecular targets for known drugs. Nature. 2009;462:175–181. [PMC free article] [PubMed]
13. Plouffe D, Brinker A, McNamara C, Henson K, Kato N, et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci USA. 2008;105:9059–9064. [PubMed]
14. Areias FM, Brea JM, Gregori-Puigjané E, Zaki MEA, Carvalho A, et al. In silico directed chemical probing of the adenosine receptor family. Bioorg Med Chem. 2010;18:3043–3052. [PubMed]
15. Vidal D, Mestres J. In silico receptorome screening of antipsychotic drugs. Mol Inf. 2010;29:543–551.
16. CancerGrid, a European Commission project under Framework Programme 6 (contract number LSHC-CT-2006-037559). Available: ftp://ftp.cordis.europa.eu/pub/lifescihealth/docs/cancergrid.pdf. Accessed: 2012 March 28.
17. Albany Molecular Research Inc (AMRI). http://www.amriglobal.com/. Accessed: 2012 March 28.
18. Clark RD. OptiSim: and extended dissimilarity selection method for finding diverse representative subsets. J Chem Inf Comput Sci. 1997;37:1181–1188.
19. Liu W, Johnson DE. Clustering and its application in multi-target prediction. Curr Opin Drug Discov Devel. 2009;12:98–107. [PubMed]
20. Gleeson MP, Hersey A, Montanari D, Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov. 2011;10:197–208. Available: http://www.ebi.ac.uk/chembldb/. Accessed: 2012 March 28. [PubMed]
21. Jensen NH, Roth BL. Massively parallel screening of the receptorome. Comb Chem High Throughput Screen. 2008;11:420–427. Ki determinations were generously provided by the National Institute of Mental Health's Psychoactive Drug Screening Program, Contract HHSN-271-2008-00025-C. Available: http://pdsp.med.unc.edu. Accessed: 2012 March 28. [PubMed]
22. Harmar AJ, Hills RA, Rosser EM, Jones M, Buneman OP, et al. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucl Acids Res. 2009;37:D680–D685. Available: http://www.iuphar-db.org. Accessed: 2012 March 28. [PMC free article] [PubMed]
23. Wang Y, Bolton E, Dracheva S, Karapetyan K, Shoemaker BA, et al. An overview of the PubChem bioassay resource. Nucl Acids Res. 2010;38:D255–D266. Available: http://pubchem.ncbi.nlm.nih.gov. [PMC free article] [PubMed]
24. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. DrugBank: a knowledge base for drugs, drug actions and drug targets. Nucl Acids Res. 2008;36:D901–D906. Available: http://www.drugbank.ca. Accessed: 2012 March 28. [PMC free article] [PubMed]
25. Liu T, Lin Y, Wen X, Jorrisen RN, Gilson MK. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucl Acids Res. 2007;35:D198–D201. Available: http://www.bindingdb.org. Accessed: 2012 March 28. [PubMed]
26. Benson ML, Smith RD, Khazanov NA, Dimcheff B, Beaver J, et al. Binding MOAD, a high-quality protein-ligand database. Nucl Acids Res. 2008;36:D674–D678. Available: http://www.bindingmoad.org. Accessed: 2012 March 28. [PMC free article] [PubMed]
27. Block P, Sotriffer CA, Dramburg I, Klebe G. AffinDB: a freely accessible database of affinities for protein-ligand complexes from the PDB. Nucl Acids Res. 2006;34:D522–D526. Available: http://pc1664.pharmazie.uni-marburg.de/affinity/. Accessed: 2012 March 28. [PMC free article] [PubMed]
28. Cases M, García-Serna R, Hettne K, Weeber M, van der Lei J, et al. Chemical and biological profiling of an annotated compound library directed to the nuclear receptor family. Curr Top Med Chem. 2005;5:763–772. [PubMed]
29. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. New Engl J Med. 2005;353:172–187. [PubMed]
30. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8:547–566. [PubMed]
31. Marks PA. The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Cell Cycle. 2004;3:534–535. [PubMed]
32. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, et al. Nature. 2003;425:407–410. [PubMed]
33. Gundem G, Perez-Llamas C, Jene-Sanz A, Kedzierska A, Islam A, et al. IntOGen: integration and data mining of multidimensional oncogenomic data. Nat Methods. 2010;7:92–93. Available: http://www.intogen.org. Accessed: 2012 March 28. [PubMed]
34. Furney SJ, Calvo B, Larrañaga P, Lozano JA, Lopez-Bigas N. Prioritization of candidate cancer genes – an aid to oncogenomic studies. Nucl Acids Res. 2008;36:e115. Available: http://bg.upf.edu/cgprio/. Accessed: 2012 March 28. [PMC free article] [PubMed]
35. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011;10:47–60. [PubMed]
36. D'Errico I, Moschetta A. Nuclear receptors, intestinal architecture and colon cancer: an intriguing link. Cell Mol Life Sci. 2008;65:1523–1543. [PubMed]
37. Macarulla T, Capdevila J, Perez-Garcia J, Ramos FJ, Elez ME, et al. New approaches and targets in advanced colorectal cancer. Eur J Cancer. 2009;45:79–88. [PubMed]
38. Slattery ML, Sweeney C, Murtaugh M, Ma KN, Caan BJ, et al. Associations between vitamin D, vitamin D receptor gene and the androgen receptor gene with colon and rectal cancer. Int J Cancer. 2006;118:3140–3146. [PubMed]
39. Cleveland AG, Oikarinen SI, Marttinen M, Rafter JJ, Gustafsson JA, et al. Disruption of estrogen receptor signaling enhances intestinal neoplasia in Apc(Min/+) mice. Carcinogenesis. 2009;30:1581–1590. [PMC free article] [PubMed]
40. Janakiram NB, Steele VE, Rao CV. Estrogen receptor-β as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res. 2009;2:52–59. [PubMed]
41. Wehler TC, Frerichs K, Graf C, Drescher D, Schimanski K, et al. PDGFRalpha/beta expression correlates with the metastatic behaviour of human colorectal cancer: a possible rationale for a molecular targeting strategy. Oncol Rep. 2008;19:697–704. [PubMed]
42. Vecchione L, Jacobs B, Normanno N, Ciardiello F, Tejpar S. EGFR-targeted therapy. Exp Cell Res. 2011;317:2765–2771. [PubMed]
43. Khelwatty SA, Essapen S, Seddon AM, Modjtahedi H. Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. Int J Oncol. 2011;39:483–491. [PubMed]
44. BioCarta pathway database. Available: http://www.biocarta.com/. Accessed: 2012 March 28.
45. Efroni S, Schaefer CF, Buetow KH. Identification of key processes underlying cancer phenotypes using biologic pathway analysis. PLoS ONE. 2007;2:e425. [PMC free article] [PubMed]
46. Menashe I, Maeder D, Garcia-Closas M, Figueroa JD, Bhattacharjee S, et al. Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. Cancer Res. 2010;70:4453–4459. [PMC free article] [PubMed]
47. Le Tourneau C, Faivre S, Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev. 2008;34:37–48. [PubMed]
48. Yde CW, Clausen MP, Bennetzen MV, Lykkesfeldt AE, Mouritsen OG, et al. The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells. Anticancer Drugs. 2009;20:723–735. [PubMed]
49. Shoemaker RH. The NCI60 human tumor cell line anticancer drug screen. Nat Rev Cancer. 2006;6:813–823. [PubMed]
50. Manning BD. Challenges and opportunities in defining the essential cancer kinome. Sci Signal. 2009;2:pe15. [PubMed]
51. Iorns E, Lord CJ, Grigoriadis A, McDonald S, Fenwick K, et al. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS ONE. 2009;4:e5120. [PMC free article] [PubMed]
52. Heijink DM, Fehrmann RSN, de Vries EGE, Koornstra JJ, Oosterhuis D, et al. A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer. Oncogene. 2011;30:2026–2036. [PubMed]
53. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov. 2011;10:712–713. [PubMed]
54. Baurin N, Baker R, Richardson C, Chen I, Foloppe N, et al. Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds. J Chem Inf Comput Sci. 2004;44:643–651. [PubMed]
55. Papp A, Gulyas-Forró A, Gulyas Z, Dormán G, Urge L, et al. Explicit Diversity Index (EDI): a novel measure for assessing the diversity of compound databases. J Chem Inf Model. 2006;46:1898–904. [PubMed]
56. Molnar L, Keserű GM, Papp A, Lorincz Z, Ambrus G, et al. A neural network classification scheme for cytotoxicity predictions: validation on 30,000 compounds. Bioorg Med Chem Lett. 2006;16:1037–1039. [PubMed]
57. Pagé B, Pagé M, Noël C. A new fluorimetric assay for cytotoxicity measurements in vitro. Int J Oncol. 1993;3:473–476. [PubMed]
58. Gregori-Puigjané E, Mestres J. SHED: Shannon entropy descriptors from topological feature distribution. J Chem Inf Model. 2006;46:1615–1622. [PubMed]
59. Vidal D, Garcia-Serna R, Mestres J. Ligand-based approaches to in silico pharmacology. Methods Mol Biol. 2011;672:489–502. [PubMed]
60. Mestres J, Seifert SA, Oprea TI. Linking pharmacology to clinical records: cyclobenzaprine and its possible association with serotonin syndrome. Clin Pharmacol Ther. 2011;90:662–665. [PubMed]
Articles from PLoS ONE are provided here courtesy of
Public Library of Science